MabCure Signs Research Agreement With Ramathibodi Hospital

MabCure has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. The study aims to evaluate MabCure’s panel of anti-ovarian MAbs in diagnosing the presence of ovarian cancer in patients suspected of having the disease.

The objective of MabCure’s clinical studies is to apply its specific antibodies for the definitive diagnosis of ovarian cancer, with the goal of early diagnosis when the disease is highly curable.

Amnon Gonenne, president and CEO of MabCure, said: “We are very excited about the commencement of this study. We have been working hard to establish key partnerships with respectable research institutions and hospitals in Europe and the Far East, and this is no exception. We are looking forward to the results of the study and to moving MabCure forward towards having our diagnostic products on the market.”

“We know our diagnostic products have the potential to save many lives, and our mission is to get them to market as quickly as possible. MabCure’s proprietary platform technology has allowed us to develop a number of cancer-specific MAbs that could be invaluable for the diagnosis of several types of lethal cancers, and we are looking forward to exploring their utility in the clinical setting as well.”